%0 Journal Article %T mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report %A Ibeas P %A Cantos B %A Provencio M. %J Blood and Lymphatic Cancer: Targets and Therapy %D 2011 %I %X Patricia Ibeas, Blanca Cantos, Mariano ProvencioClinical Oncology Department, Hospital Puerta de Hierro Majadahonda, Madrid, SpainAbstract: Hodgkin¡¯s disease is curable in 90% of the cases diagnosed in early stages (I and II) and in 70% of all patients who suffer from the disease. Refractory disease occurs in 10%¨C15% of cases and is still a clinical challenge. Its treatment is based on intensive chemotherapy regimens with transplantation, but there are patients who relapse after transplantation who have a poor prognosis. At this point in time, there is a lack of effective treatment options with proven efficacy and there is a real need to investigate new treatment drugs with different mechanisms of action. A persistent activation of mTOR signaling has been identified in leukemia, Hodgkin¡¯s and non-Hodgkin¡¯s lymphoma, and multiple myeloma. Everolimus, an mTOR kinase inhibitor, is being used as an option in these cases with encouraging results. Here, the authors report their experience with a patient treated with everolimus.Keywords: everolimus, positron emission tomography, chemotherapy %U http://www.dovepress.com/mtor-inhibitor-in-the-treatment-of-hodgkinrsquos-lymphoma-a-case-repor-a8613